|
Drug Resistance in Pneumocystis jirovecii Causing Severe Pneumonia
Researchers report that Pneumocystis jirovecii, a fungus that can cause severe pneumonia in people with weakened immune systems, appears to have become resistant to a drug not intended to kill it. The news highlights updated study findings related to drug resistance in P. jirovecii-associated pneumonia.
Pneumocystis jirovecii and Pneumocystis pneumonia:
| Dimension | Key Details |
|---|---|
| Pathogen type | Pneumocystis jirovecii is an opportunistic fungal pathogen. |
| At-risk groups | It can cause pneumonia in patients with impaired immune systems, such as those with AIDS or who are receiving immunosuppressive drugs. |
| Transmission | It is a ubiquitous organism transmitted by aerosol route. |
| Effect in immunocompetent patients | It causes no disease in immunocompetent patients. |
| Classification status | Initially classified as a protozoa, it has been considered a fungus since the 1990s based on molecular analyses. |
| Life cycle forms | Its life cycle primarily consists of trophic (eg, trophozoites) and cystic forms. |
| PCP (definition) | Pneumocystis pneumonia (PCP) is a lung infection that mainly affects people with weakened immune systems. |
| PCP causative agent | The fungus Pneumocystis jirovecii causes PCP. |
| PCP signs and symptoms | Signs and symptoms comprise fever, chills, cough, shortness of breath (dyspnea), and fatigue. |
| PCP transmission route | P. jirovecii is transmitted from one person to another through the air when someone coughs, sneezes, or talks. |
| Treatment | It is treated with high doses of the antibiotic trimethoprim-sulfamethoxazole (TMP-SMX). |